vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and Valens Semiconductor Ltd. (VLN). Click either name above to swap in a different company.
CytomX Therapeutics, Inc. is the larger business by last-quarter revenue ($18.7M vs $17.3M, roughly 1.1× Valens Semiconductor Ltd.). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -42.2%, a 41.4% gap on every dollar of revenue. On growth, Valens Semiconductor Ltd. posted the faster year-over-year revenue change (8.1% vs -25.7%). Valens Semiconductor Ltd. produced more free cash flow last quarter ($-4.9M vs $-15.8M).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Valens Semiconductor (Valens) is an Israeli fabless manufacturing company providing semiconductors for the automotive and audio-video industries. Valens provides semiconductor products for the distribution of uncompressed ultra-high-definition (UHD) multimedia content and in-vehicle connectivity applications. The company is a member of the MIPI Alliance and developed the first-to-market chipset that is compliant with the MIPI A-PHY standard. Valens invented the technology behind the HDBaseT s...
CTMX vs VLN — Head-to-Head
Income Statement — Q2 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $17.3M |
| Net Profit | $-154.0K | $-7.3M |
| Gross Margin | — | 63.0% |
| Operating Margin | -6.9% | -46.4% |
| Net Margin | -0.8% | -42.2% |
| Revenue YoY | -25.7% | 8.1% |
| Net Profit YoY | 97.6% | 29.3% |
| EPS (diluted) | — | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $17.3M | ||
| Q2 25 | $18.7M | $17.1M | ||
| Q1 25 | $50.9M | $16.8M | ||
| Q4 24 | $38.1M | — | ||
| Q3 24 | $33.4M | $16.0M | ||
| Q2 24 | $25.1M | $13.6M | ||
| Q1 24 | $41.5M | — | ||
| Q4 23 | $26.6M | — |
| Q3 25 | — | $-7.3M | ||
| Q2 25 | $-154.0K | $-7.2M | ||
| Q1 25 | $23.5M | $-8.3M | ||
| Q4 24 | $18.9M | — | ||
| Q3 24 | $5.7M | $-10.4M | ||
| Q2 24 | $-6.5M | $-8.9M | ||
| Q1 24 | $13.8M | — | ||
| Q4 23 | $837.0K | — |
| Q3 25 | — | 63.0% | ||
| Q2 25 | — | 63.5% | ||
| Q1 25 | — | 62.9% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.4% | ||
| Q2 24 | — | 61.4% | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
| Q3 25 | — | -46.4% | ||
| Q2 25 | -6.9% | -43.3% | ||
| Q1 25 | 44.4% | -56.2% | ||
| Q4 24 | 46.4% | — | ||
| Q3 24 | 12.3% | -76.3% | ||
| Q2 24 | -33.7% | -69.2% | ||
| Q1 24 | 28.1% | — | ||
| Q4 23 | -2.3% | — |
| Q3 25 | — | -42.2% | ||
| Q2 25 | -0.8% | -42.1% | ||
| Q1 25 | 46.2% | -49.4% | ||
| Q4 24 | 49.6% | — | ||
| Q3 24 | 17.2% | -64.6% | ||
| Q2 24 | -26.0% | -65.2% | ||
| Q1 24 | 33.3% | — | ||
| Q4 23 | 3.1% | — |
| Q3 25 | — | $-0.07 | ||
| Q2 25 | — | $-0.07 | ||
| Q1 25 | — | $-0.08 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.10 | ||
| Q2 24 | — | $-0.08 | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $93.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $108.8M |
| Total Assets | $175.1M | $136.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $93.5M | ||
| Q2 25 | $49.0M | $102.7M | ||
| Q1 25 | $47.6M | $112.5M | ||
| Q4 24 | $38.1M | — | ||
| Q3 24 | $40.6M | $133.1M | ||
| Q2 24 | $43.2M | $105.9M | ||
| Q1 24 | $36.2M | — | ||
| Q4 23 | $17.2M | — |
| Q3 25 | — | $108.8M | ||
| Q2 25 | $119.9M | $116.5M | ||
| Q1 25 | $25.0M | $128.6M | ||
| Q4 24 | $-456.0K | — | ||
| Q3 24 | $-23.5M | $147.0M | ||
| Q2 24 | $-31.2M | $153.5M | ||
| Q1 24 | $-31.7M | — | ||
| Q4 23 | $-47.4M | — |
| Q3 25 | — | $136.7M | ||
| Q2 25 | $175.1M | $144.8M | ||
| Q1 25 | $98.5M | $154.6M | ||
| Q4 24 | $120.5M | — | ||
| Q3 24 | $139.0M | $171.9M | ||
| Q2 24 | $159.2M | $175.8M | ||
| Q1 24 | $184.7M | — | ||
| Q4 23 | $201.8M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $-4.7M |
| Free Cash FlowOCF − Capex | $-15.8M | $-4.9M |
| FCF MarginFCF / Revenue | -84.6% | -28.5% |
| Capex IntensityCapex / Revenue | 0.1% | 1.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $-11.0M |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-4.7M | ||
| Q2 25 | $-15.8M | $-211.0K | ||
| Q1 25 | $-21.0M | $-7.6M | ||
| Q4 24 | $-19.9M | — | ||
| Q3 24 | $-20.7M | $3.0M | ||
| Q2 24 | $-19.5M | $-225.0K | ||
| Q1 24 | $-26.0M | — | ||
| Q4 23 | $-22.0M | — |
| Q3 25 | — | $-4.9M | ||
| Q2 25 | $-15.8M | $-330.0K | ||
| Q1 25 | $-21.2M | $-8.0M | ||
| Q4 24 | $-20.0M | — | ||
| Q3 24 | $-20.7M | $2.2M | ||
| Q2 24 | $-19.6M | $-460.0K | ||
| Q1 24 | $-26.2M | — | ||
| Q4 23 | $-22.2M | — |
| Q3 25 | — | -28.5% | ||
| Q2 25 | -84.6% | -1.9% | ||
| Q1 25 | -41.6% | -47.3% | ||
| Q4 24 | -52.5% | — | ||
| Q3 24 | -62.1% | 14.0% | ||
| Q2 24 | -78.2% | -3.4% | ||
| Q1 24 | -63.1% | — | ||
| Q4 23 | -83.5% | — |
| Q3 25 | — | 1.6% | ||
| Q2 25 | 0.1% | 0.7% | ||
| Q1 25 | 0.2% | 2.1% | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.1% | 4.5% | ||
| Q2 24 | 0.4% | 1.7% | ||
| Q1 24 | 0.3% | — | ||
| Q4 23 | 1.0% | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.89× | — | ||
| Q4 23 | -26.24× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
VLN
Segment breakdown not available.
